Main Article Content
A pilot study was conducted to evaluate the effect of nizatidine on olanzapine-associated weight gain (OAWG) in ten patientswith schizophrenia and schizophreniform disorder in Korea. Psychometric ratings with positive and negative syndromescale (PANSS) and brief psychiatric rating scale (BPRS) were measured at baseline, week 4 and week 8; as were weight and bodymass index (BMI). A combination of nizatidine for 8 weeks resulted in significant reversal of weight gain without worsening thepsychopathology (weight: 3.5% and BMI: 3.7%). In line with studies of Western populations, an add-on therapy of nizatidinecould be an effective option for the control of weight gain in olanzapine-treated patients in Korea. Our findings call for furtherevaluation of the effect of this drug on OAWG, with randomized placebo-controlled studies, in Asian populations.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).